Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

116
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
116
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

116
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
116
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

155
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
155
Pancreas01:19

Pancreas

812
The pancreas, an essential organ in the human body, is a pinkish-gray elongated structure located posterior to the stomach. It extends laterally from the duodenum towards the spleen and is firmly bound to the posterior wall of the abdominal cavity. The organ's surface has a lumpy, lobular texture that gives it a unique appearance.
The broad head of the pancreas lies within the loop formed by the duodenum, while its slender body reaches towards the spleen. The tail of the pancreas is short...
812
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

418
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
418

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cancer Frequencies and Screening in Individuals With Down Syndrome: A Comprehensive Nationwide Cross-Sectional Analysis.

JCO global oncology·2026
Same author

Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.

Gastroenterology research·2026
Same author

ATM Deficiency Induces TGF-β-Mediated Stromal Programming in Pancreatic Cancer.

Cancer research·2026
Same author

Pancreatic cancer.

Nature reviews. Disease primers·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

857

Pancreatic Cancer:

Fergus Keane1,2, Catherine A O'Connor1,2, Wungki Park1,2,3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cancers
|June 10, 2023
PubMed
Summary
This summary is machine-generated.

Pancreatic cancer (PDAC) treatments are improving for patients with BRCA mutations. Research is expanding PARP inhibitor use to other DNA damage repair gene mutations, addressing resistance challenges.

Keywords:
BRCAPARP inhibitorshomologous recombinationpancreatic cancerplatinumtargeted therapy

More Related Videos

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
08:12

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique

Published on: February 2, 2022

2.1K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

464

Related Experiment Videos

Last Updated: Jul 27, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

857
Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
08:12

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique

Published on: February 2, 2022

2.1K
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

464

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited treatment options.
  • Germline BRCA1/2 mutations define a subgroup of PDAC patients with better prognosis and targeted therapies.
  • PARP inhibitors offer new hope for BRCA-mutated PDAC but resistance is a challenge.

Purpose of the Study:

  • To review the current treatment landscape for PDAC with BRCA1/2 and other DNA damage repair (DDR) gene mutations.
  • To discuss experimental therapeutic approaches and future directions for managing PDAC.
  • To highlight the challenges of primary and acquired resistance to therapies.

Main Methods:

  • Literature review of current and emerging treatments for PDAC.
  • Analysis of clinical trials investigating PARP inhibitors and other DDR-targeting agents.
  • Discussion of resistance mechanisms and strategies to overcome them.

Main Results:

  • BRCA-mutated PDAC patients benefit from PARP inhibitors and platinum-based chemotherapy.
  • Ongoing trials explore expanding PARP inhibitor indications to other DDR-deficient PDAC.
  • Resistance to current therapies remains a significant hurdle for long-term patient outcomes.

Conclusions:

  • Biomarker-driven therapy, including PARP inhibition, is transforming PDAC management for specific subgroups.
  • Further research is crucial to overcome therapeutic resistance and improve survival in PDAC.
  • Expanding treatment strategies to encompass a broader range of DDR mutations is a key future direction.